IL309278A - Bis-benzimidazole STING agonist conjugates and uses thereof - Google Patents
Bis-benzimidazole STING agonist conjugates and uses thereofInfo
- Publication number
- IL309278A IL309278A IL309278A IL30927823A IL309278A IL 309278 A IL309278 A IL 309278A IL 309278 A IL309278 A IL 309278A IL 30927823 A IL30927823 A IL 30927823A IL 309278 A IL309278 A IL 309278A
- Authority
- IL
- Israel
- Prior art keywords
- benzimidazole
- bis
- sting agonist
- agonist immunoconjugates
- immunoconjugates
- Prior art date
Links
- 229940044665 STING agonist Drugs 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163215100P | 2021-06-25 | 2021-06-25 | |
| PCT/US2022/034865 WO2022272039A1 (en) | 2021-06-25 | 2022-06-24 | Bis-benzimidazole sting agonist immunoconjugates, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309278A true IL309278A (en) | 2024-02-01 |
Family
ID=82850579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309278A IL309278A (en) | 2021-06-25 | 2022-06-24 | Bis-benzimidazole STING agonist conjugates and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250057967A2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4359007A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024523453A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240027018A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117794583A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022300383A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3222082A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309278A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022272039A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024137619A1 (en) * | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| WO2024174863A1 (zh) * | 2023-02-22 | 2024-08-29 | 深圳众格生物科技有限公司 | Sting激动剂及其制备方法和医药用途 |
| AU2024315750A1 (en) | 2023-07-31 | 2026-03-05 | Sutro Biopharma, Inc. | Sting agonist compounds and conjugates |
| CN117771206B (zh) * | 2023-08-02 | 2024-05-28 | 首都医科大学附属北京儿童医院 | Sting激动剂仿生纳米递送系统及其制备方法和应用 |
| WO2025233679A1 (en) * | 2024-05-08 | 2025-11-13 | Ligachem Biosciences Inc. | Compositions and methods related to a combination therapy of sting agonists and antibody drug conjugates |
| TW202604486A (zh) * | 2024-05-08 | 2026-02-01 | 韓商瑞嘉化學生物科學股份有限公司 | 與sting促效劑及免疫檢查點抑制劑之組合療法相關之組合物及方法 |
| TW202613130A (zh) | 2024-05-30 | 2026-04-01 | 日商安斯泰來製藥股份有限公司 | Sting促效劑免疫刺激性抗體藥物結合物 |
| WO2026055185A1 (en) * | 2024-09-04 | 2026-03-12 | Bolt Biotherapeutics, Inc. | Sting agonist immunoconjugates and uses thereof |
| WO2026078593A1 (en) | 2024-10-08 | 2026-04-16 | Sun Pharma Advanced Research Company Limited | Sting agonists and antibody drug conjugates thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201900628RA (en) * | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| AR113224A1 (es) * | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| AU2018344902B2 (en) * | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| US11377440B2 (en) * | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| CN118846110A (zh) * | 2018-09-06 | 2024-10-29 | 第一三共株式会社 | 抗体药物偶联物 |
| CN113348181A (zh) * | 2018-10-31 | 2021-09-03 | 诺华股份有限公司 | 包含sting激动剂的dc-sign抗体缀合物 |
| JP2022529183A (ja) * | 2019-04-17 | 2022-06-17 | アヴィディア テクノロジーズ, インコーポレイテッド | リガンド提示および/または薬物送達のためのスターポリマーを製造する組成物および方法 |
| TWI925817B (zh) * | 2019-05-10 | 2026-05-21 | 日商武田藥品工業股份有限公司 | 抗體藥物結合物 |
| JP2022537158A (ja) * | 2019-06-13 | 2022-08-24 | ボルト バイオセラピューティクス、インコーポレーテッド | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
| US11033635B2 (en) * | 2019-07-19 | 2021-06-15 | Immunesensor Therapeutics, Inc. | Antibody-STING agonist conjugates and their use in immunotherapy |
| CN116196435B (zh) * | 2020-04-02 | 2025-12-02 | 梅尔莎纳医疗公司 | 包含sting激动剂的抗体药物缀合物 |
-
2022
- 2022-06-24 US US18/573,094 patent/US20250057967A2/en active Pending
- 2022-06-24 WO PCT/US2022/034865 patent/WO2022272039A1/en not_active Ceased
- 2022-06-24 JP JP2023578817A patent/JP2024523453A/ja active Pending
- 2022-06-24 CA CA3222082A patent/CA3222082A1/en active Pending
- 2022-06-24 CN CN202280053551.7A patent/CN117794583A/zh active Pending
- 2022-06-24 EP EP22753804.8A patent/EP4359007A1/en not_active Withdrawn
- 2022-06-24 AU AU2022300383A patent/AU2022300383A1/en not_active Abandoned
- 2022-06-24 IL IL309278A patent/IL309278A/en unknown
- 2022-06-24 KR KR1020247002332A patent/KR20240027018A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117794583A (zh) | 2024-03-29 |
| US20250057967A2 (en) | 2025-02-20 |
| WO2022272039A1 (en) | 2022-12-29 |
| CA3222082A1 (en) | 2022-12-29 |
| EP4359007A1 (en) | 2024-05-01 |
| JP2024523453A (ja) | 2024-06-28 |
| AU2022300383A1 (en) | 2024-01-18 |
| KR20240027018A (ko) | 2024-02-29 |
| US20240335557A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022300383A1 (en) | Bis-benzimidazole sting agonist immunoconjugates, and uses thereof | |
| IL288816A (en) | Aminobenzazepine compounds, immunoconjugates and uses thereof | |
| GB2567907B (en) | Protection device, assembly and method | |
| IL289740A (en) | Macrocyclic compounds as sting agonists and their methods and uses | |
| EP3366741A4 (en) | COATING SOLUTION AND GAS BARRIER LAMINATE | |
| EP2876438A4 (en) | HEADSPACE SAMPLE INTRODUCTION AND GAS CHROMATOGRAPH THEREWITH | |
| GB201909486D0 (en) | Compositons, uses and methods | |
| ZA202007187B (en) | Solubilized apyrases, methods and use | |
| ZA202109377B (en) | Handheld measurement, search and safety device | |
| PL4223745T3 (pl) | Związek amidu dendrenu, środek bakteriobójczy i jego zastosowanie | |
| SG11202102506PA (en) | Card-handling devices and related methods, assemblies, and components | |
| HK40111013A (en) | Bis-benzimidazole sting agonist immunoconjugates, and uses thereof | |
| IL291071B1 (en) | Cell, structure, and building block | |
| HK40109557A (en) | Asymmetric bis-benzimidazole sting agonist immunoconjugates and uses thereof | |
| PL4422770T3 (pl) | Urządzenie do cięcia, układ i zastosowanie | |
| PH12021553228A1 (en) | Hole cutting and trepanning device | |
| GB201910299D0 (en) | Medical uses, methods and uses | |
| AU2022245340A1 (en) | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof | |
| GB202109510D0 (en) | Copolymers and related methods, uses and components | |
| GB202109266D0 (en) | Copolymers and related methods, uses and components | |
| PL4173687T3 (pl) | Urządzenie ścinające, układ i zastosowanie | |
| GB2635302B (en) | Fungicidal combinations, methods, and applications thereof | |
| HK40098741B (en) | Sting antagonists and uses thereof | |
| HK40099164A (en) | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof | |
| HK40086597A (en) | Pyrazoloazepine immunoconjugates, and uses thereof |